$SNY (-0,8%)

- Revenue: €10.56B, +10.3% YoY at CER

- Net income: €683M vs -€555M in Q4 2023

- Business EPS: €1.31, -11.0% YoY at CER

- Full year revenue: €41.1B, +11.3% YoY at CER

CEO Paul Hudson: "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales."

🌱Revenue & Growth

- US sales: €5.15B, +13.3% YoY at CER

- Europe sales: €2.43B, +6.0% YoY at CER

- Rest of World: €2.98B, +8.8% YoY at CER

- Dupixent sales: €3.46B, +16.0% YoY at CER

- Vaccines sales: €2.18B, +10.8% YoY at CER

💰Profits & Financials

- Gross margin: 74.3%, -2.5pp YoY

- Business operating income: €2.08B, -7.7% YoY at CER

- Free cash flow: €2.34B, -25.5% YoY

- R&D expenses: €2.26B, +24.4% YoY

📌Business Highlights

- Received 14 regulatory approvals of medicines and vaccines in 2024

- Beyfortus achieved blockbuster status with €1.7B sales in first full year

- Plans to sell controlling stake in Opella consumer health business

🔮Future Outlook

- 2025 sales growth expected at mid-to-high single-digit percentage at CER

- Expects strong rebound in business EPS with low double-digit growth at CER

- Plans €5B share buyback program in 2025

- Dupixent sales expected to reach around €22B by 2030